体外药效检测平台

南模生物体外药效检测服务平台聚焦于靶标验证、药物筛选、药物体外功能学及联合体内药理药效团队开展的药物机理研究,配备有高阶多色流式检测、细胞单/多因子检测、DNA/RNA相关检测、血常规血生化检测和Western Blot等技术平台,同时可提供细胞活性测试、ADCC/TDCC、MLR试验、CDC试验、ADC旁观者试验等相关细胞实验服务。
平台配备了全面先进的检测设备

支持多种样品类型

能够处理骨髓、脑脊液、不同抗凝剂处理的血浆、细胞裂解液、细胞上清液等多种复杂样本

支持微量样品检测

流式可低至纳米级颗粒或10 μL上样体积,ELISA可检出fg/mL级别的生物标志物,可检出20万-30万中的1个阳性细胞

分析检测速度快,灵敏度高

流式上样速度高达30,000 events/s;ELISA支持四通道荧光成像和明场成像
Transdermal Mini GFR Monitor,
MediBeacon
MSD SQ120
EnSight
AID ELISPOT
CytoFLEX Flow Cytometer
Rad Source RS2000 XE
Ex vivo 药效检测服务
In vitro 药效检测服务
PD检测服务

服务项目

  • 免疫细胞分析
  • 肿瘤浸润淋巴细胞分析
  • 多细胞因子分析
  • 受体占位(RO)分析

服务案例

image.png

Fig. FACS detection of immune cell infiltration in subcutaneous graft tumours.(**P<0.01,*P<0.05)

SMOC provides a comprehensive portfolio of predefifined cytokine panels, offffering flflexible selection aligned with drug mechanisms and experimental objectives. Our assays achieve high sensitivity down to 10 pg/mL, with select ultra-sensitive platforms reaching 274 fg/mL. Detection  covers diverse biospecimens—including serum, plasma, tears, aqueous humor, saliva, body cavity lavage flfluids, cell supernatants, and tissue  lysates—across mouse, rat, non-human primate, and human for immunology, oncology, neurology, and functional research.

image.png

image.png

PK检测服务

服务项目

  • PK 试验
  • LC/MS 检测小分子多肽类药物
  • ELISA 方法检测抗体类药物
  • Abs/ADA 检测等

服务案例

In vitro 药效检测服务利用原代细胞与细胞系,针对候选抗体药物的结合能力、Fc相关功能特性,Fab相关功能特性等体外药理学进行检测与评价,为药物的体外筛选和功能性检测提供支持。

服务项目

  • ADCC/TDCC
  • MLR 试验
  • CDC 试验
  • ADC 旁观者试验

服务案例

The mixed lymphocyte reaction (MLR) is commonly used to determine the degree of compatibility between the major histocompatibility complex (HLA) antigens of a recipient and a donor. It is a system involving the co-culture of primary dendritic cells (DCs) and T cells, and is frequently used to assess DC-mediated T cell activation.

image.png

Sample: mDC+CD4+T cells+Compound

Vehicle control: mDC+CD4+T cells+Medium

Medium: Medium

Antibody-based therapies often require the use of the complement-dependent cytolysis (CDC) assay to evaluate their efficacy. The CDC assay assesses the ability of a candidate drug to destroy specific target cells through multiple pathways mediated by the complement system.

The CDC assay typically involves incubating target cells, the antibody under test, and serum (as a source of complement) together at 37°C for 1–24 hours, after which the lysed dead cells or live cells can be examined.


image.png

Antibody-dependent cellular cytotoxicity (ADCC) is a key immune mechanism in which effector cells lyse target cells via membrane surface antigens bound by specific antibodies; it also forms the basis for many current antibody therapies.

image.png

When the drug in an ADC is released after being internalized and degraded within the target cell, or when it is released into the extracellular space, it induces bystander killing, which is one of the key mechanisms by which ADCs exert their effects.

image.png

微信咨询 qrcode上海南方模式生物科技股份有限公司官方微信公众号二维码 请拨打 400 728 0660 南模生物联系方式电话图标 在线咨询 南模生物在线资讯图标-点击开始在线资讯 回到顶部 点击跳转到顶部